Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor (“EGFRi”) to bring in $10 million upfront payment and expand dataset to combination therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback